The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 6, 2011, Pages 3174-3180

  Murphy, Christopher J ^a,b,c   Bentley, Ellison ^a   Miller, Paul E ^a   McIntyre, Kim ^a   Leatherberry, Gary ^a   Dubielzig, Richard ^a   Giuliano, Elizabeth ^d   Moore, Cecil P ^d   Phillips, Thomas E ^e   Smith, Peter B ^f   Prescott, Elizabeth ^f   Miller, Jacqueline M ^f   Thomas, Peter ^f   Scagliotti, Randall ^g   Esson, Doug ^g   Gadek, Tom ^h   O'Neill, Charles A ^h  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

^e UNIVERSITY OF MISSOURI   (United States)

^f 206 Carnegie Center   (United States)

^g Eye Care For Animals   (United States)

^h SARcode Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RECOMBINANT INTERCELLULAR ADHESION MOLECULE 1; SAR 1118; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; EYE DROPS; INTERCELLULAR ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CONJUNCTIVAL BIOPSY; CONTROLLED STUDY; DOG; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE EXAMINATION; FEMALE; HUMAN; HUMAN CELL; KERATOCONJUNCTIVITIS SICCA; LYMPHOCYTE ACTIVATION; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; SCHIRMER TEST; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; ANIMAL; ANIMAL DISEASE; DOG DISEASE; DOSE RESPONSE; DRUG EFFECT; LEUKEMIA CELL LINE; METABOLISM; MONONUCLEAR CELL; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; CELL ADHESION; CYTOKINES; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; JURKAT CELLS; KERATOCONJUNCTIVITIS SICCA; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MALE; OPHTHALMIC SOLUTIONS;

EID: 79960959962     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-5078     Document Type: Article

References (28)

1. Sansom J, Barnett K, Long R. Keratoconjunctivitis sicca in the dog associated with the administration of salicylazosulphapyridine (sulphasalazine). Vet Rec. 1985;116:391-393.
2. Majeed S, Gopinath C, Heywood R. A report on drug-induced keratoconjunctivitis sicca in dogs. J Comp Pathol. 1987;97:385-391.
3. Gipson I, Argeso P, Beuerman R, et al. Research in dry eye: report of the Research Subcommittee of the International Dry Eye Work-Shop (2007). Ocul Surf. 2007;5:179-193.
4. Kassan S, Moutsopoulos H. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med. 2004;164:1275-1284.
5. Barnett K, Sansom J. Diagnosis and treatment of keratoconjunctivitis sicca in the dog. Vet Rec. 1987;120:340-345.
6. Carrington S, Jones S, Lightfoot R, Bedford P. Keratoconjunctivitis in the dog. Vet Rec. 1987;121:115.
7. Kaswan R, Martin C, Dawe D. Keratoconjunctivitis sicca: immunological evaluation of 62 canine cases. Am J Vet Res. 1985;46:376-383.
8. Kaswan R, Martin C, Chapman WL Jr. Keratoconjunctivitis sicca: histopathologic study of nictitating membrane and lacrimal glands from 28 dogs. Am J Vet Res. 1984;45:112-118.
9. Gao J, Morgan G, Tieu D, et al. ICAM-1 expression predisposes ocular tissue to immune-based inflammation in dry eye patients and Sjögren syndrome-like MRL/lpr mice. Exp Eye Res. 2004;78: 823-835.
10. Zecchinon L, Fett T, Vanden Bergh P, Desmecht D. Key roles of LFA-1 in leukocyte migration and immune response. Clin Appl Immunol Rev. 2006;6:191-200.
11. Gumus K, Cavanagh D. The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca. Clin Ophthalmol. 2009;3:57-67.
12. Kunert K, Tisdale A, Gipson I. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120:330-337.
13. Stern M, Gao J, Schwalb T, et al. Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci. 2002;43:2609-2614.
14. De Paiva CS, Hwang CS, Pitcher JD 3rd, et al. Age-related T-cell cytokine profile parallels corneal disease severity in Sjogren's syndrome-like keratoconjunctivitis sicca in CD25KO mice. Rheumatology (Oxford). 2010;49:246-258.
15. Chauhan S, El Annan J, Ecoiffier T, et al. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol. 2009;182:1247-1252.
16. Morgan R, Abrams K. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs. J Am Vet Med Assoc. 1991;199:1043-1046.
17. Olivero D, Davidson M, English R, Nasisse M, Jamieson V, Gerig T. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. J Am Vet Med Assoc. 1991;199: 1039-1042.
18. Izci C, Celik I, Alkan F, et al. Histologic characteristics and local cellular immunity of the gland of the third eyelid after topical ophthalmic administration of 2% cyclosporine for treatment of dogs with keratoconjunctivitis sicca. Am J Vet Res. 2002;63:688-694.
19. Tang-Liu D, Acheampong A. Ocular pharmacokinetics and safety of cyclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet. 2005;44:247-261.
20. Stonecipher K, Perry H, Gross R, Kerney D. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Curr Med Res Opin. 2005;21:1057-1063.
21. Berdoulay A, English R, Nadelstein B. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. Vet Ophthalmol. 2005;8:225-232.
22. Ofri R, Lambrou G, Allgoewer I, et al. Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A. Vet J. 2009;179:70-77.
23. Gadek T, Burdick D, McDowell R, et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science. 2002;295:1086-1089.
24. Keating S, Clark K, Stefanich L, et al. Competition between intercellular adhesion molecule-1 and a small-molecule antagonist for a common binding site on the alpha-l subunit of lymphocyte function-associated antigen-1. Protein Sci. 2006;15:290-303.
25. Hackett R, McDonald T. Eye irritation. In: Marzulli F, Maibach H, eds. Advances in Modern Toxicology: Dermatoxicology. Washington, DC: Hemisphere Publishing; 1991:749-815.
26. Lam H, Bleiden L, De Paiva C, Farley W, Stern M, Pflugfelder S. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol. 2009;147:198-205.
27. Levels of cyclosporine at the cornea surface have been measured at 254 ng/gram of tissue (0.00021 μM) 12 hours after a bid dose of 0.05% Cyclosporine to the normal dog eye. See slide 128, www.fda.gov/ohrms/dockets/ac/99/slides/3533/3533s1c.ppt. Accessed April 9, 2011.
28. Semba C, Swearingen D, Smith V, et al. Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 (LFA-1) antagonist ophthalmic solution (SAR 1118) in healthy adults. J Ocul Pharmacol Therapeut. 2011;27:99-104.